干扰素-α治疗慢性乙型肝炎疗效与HLA-DRB_1等位基因相关性研究  

The relationship between interferon treatment in patients with chronic B and HLA-DRB_1*07

作　　者：李玮[1] 

机构地区：[1]山东省青岛大学/青岛传染病院,266033

出　　处：《中国实用医药》2009年第29期34-35,共2页China Practical Medicine

摘　　要：目的探讨人白细胞抗原-DRB1等位基因与干扰素-α治疗慢性乙型肝炎疗效的关系。方法以45例接受干扰素治疗24个月的慢性乙型肝炎患者做为研究对象,应用聚合酶联-序列特异性引物(PCR-SSP)技术对患者的HLA-Ⅱ类抗原的DRB1*07进行等位基因检测,SPSS 10.0统计软件进行结果分析。结果45例慢性乙型肝炎中有应答的32例,占71.1%,无应答的13例,占28.9%。无应答组中HLA-RB1*07出现频率较应答高。结论干扰素-α治疗无应答与HLA-DRB1*07相关。检测HLA-DRB1等位基因有助于临床医师预测患者对干扰素的疗效。Objective To investigate the relationship between interferon-αtreatment in patients with chronic B and HLA-DRB1 ＊ 07. Methods Forty-five patients with chronic B were treated with 5MU interferon- αevery other day for twenty-four weeks. HLA-DRB1 ＊ 07 were detected by using polymerase chain reaction-sequence specific primer（PCR-SSP） technique. The data were analyzed by SPSS11.0 software. Results Among the 45cases there were 32 cases（71.1% ）in the responsive group and 13 cases（28. 9% ）in the non_responsive group. The frequency of HLA-DRB1 ＊ 07 in non_responders was higher than that in the responders. Conclusion No response of interferon-αtherapy in patients with chronic B was correlated positively with HLA-DRB1 ＊ 07. Detecting the HLA-DRB1 ＊ 07 gene helps in predicting the therapeutic effects of interferon.

关 键 词：慢性乙型肝炎 干扰素-Α HLA抗原 

分 类 号：R512.62[医药卫生—内科学] R725.5[医药卫生—临床医学]